Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

NPC-18688 displays long-lasting antihyperalgesic effects in rodents

April 26, 1996

SKB claims morphinoid derivatives

April 26, 1996

OT-7100, Otsuka's new analgesic for peripheral pain

April 26, 1996

Combined thrombolytic/neuroprotective agents more effective in treating stroke

April 19, 1996

Nerve growth synthesis inducers produce neuroprotective effects

April 19, 1996

SKB reports calcium antagonists for stroke

April 19, 1996

New Takeda compounds suppress increased vascular permeability

April 19, 1996

Lilly reports cannabinoid receptor antagonists

April 19, 1996

Dolasetron submitted for approval in U.S.

April 19, 1996

Cerebyx approvable in USA

April 19, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...